argenxARGX
ARGX
About: Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Employees: 1,639
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
129% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 34
107% more call options, than puts
Call options by funds: $375M | Put options by funds: $181M
22% more repeat investments, than reductions
Existing positions increased: 144 | Existing positions reduced: 118
11% more funds holding
Funds holding: 352 [Q3] → 390 (+38) [Q4]
11% more capital invested
Capital invested by funds: $19B [Q3] → $21B (+$2.01B) [Q4]
2.07% less ownership
Funds ownership: 58.59% [Q3] → 56.52% (-2.07%) [Q4]
10% less funds holding in top 10
Funds holding in top 10: 20 [Q3] → 18 (-2) [Q4]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$680
14%
upside
Avg. target
$770
29%
upside
High target
$1,100
85%
upside
8 analyst ratings
7 positive
88%
1 neutral
13%
0 negative
0%
Citigroup Samantha Semenkow 27% 1-year accuracy 3 / 11 met price target | 34%upside $796 | Buy Maintained | 17 Apr 2025 |
Wedbush David Nierengarten 33% 1-year accuracy 40 / 120 met price target | 20%upside $715 | Outperform Reiterated | 16 Apr 2025 |
HC Wainwright & Co. Douglas Tsao 17% 1-year accuracy 30 / 172 met price target | 21%upside $720 | Buy Reiterated | 11 Apr 2025 |
Guggenheim Yatin Suneja 18% 1-year accuracy 6 / 34 met price target | 85%upside $1,100 | Buy Maintained | 10 Mar 2025 |
Baird Joel Beatty 21% 1-year accuracy 8 / 38 met price target | 14%upside $680 | Neutral Maintained | 4 Mar 2025 |
Financial journalist opinion
Based on 10 articles about ARGX published over the past 30 days
Positive
Zacks Investment Research
22 hours ago
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?
Positive
Zacks Investment Research
3 days ago
Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last?
Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Positive
Benzinga
6 days ago
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE's ARGX Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Neutral
GlobeNewsWire
6 days ago
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 27, 2025 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands. The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders.
Positive
Investors Business Daily
1 week ago
Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug
Argenx stock jumped Friday after the FDA cleared its autoimmune disease drug, Vyvgart Hytrulo, for at-home treatment. The post Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug appeared first on Investor's Business Daily.
Positive
Reuters
1 week ago
US FDA approves syringe version of Argenx's immune disorder drug
The U.S. Food and Drug Administration has approved a pre-filled syringe version of Netherlands-based Argenx SE's blockbuster immune disorder drug, Vyvgart, giving patients the more convenient option of at-home self administration, the company said on Thursday.
Neutral
GlobeNewsWire
1 week ago
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for when and where to receive treatment – at home, while ‘on the go' or in a healthcare setting Approval reflects commitment to innovating the patient experience with individualized, safe and effective therapies April 10, 2025, 11:45 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) approved a new option for patients to self-inject VYVGART® Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). “Today's FDA approval provides a new self-injection option across both approved indications in the U.S. that is designed for patients who seek more independence with their treatment,” said Luc Truyen M.D.
Neutral
GlobeNewsWire
1 week ago
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term CIDP data demonstrating VYVGART Hytrulo's durable efficacy, sustained functional improvements and favorable safety profile argenx continues to advance a robust neuromuscular pipeline of clinical candidates; first-in-human data of ARGX-119 (MuSK agonist) support pipeline-in-a-product development plan April 8, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of 15 abstracts, including an oral presentation, at the 2025 American Academy of Neurology (AAN) Annual Meeting from April 5 – 9, 2025 in San Diego, CA. The presentations showcase long-term data of VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) with a favorable safety profile.
Neutral
Seeking Alpha
1 week ago
Stock Picks From Seeking Alpha's March 2025 New Analysts
In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT, financials, utilities, materials, and mining—and provided ratings ranging from Strong Sell to Strong Buy. Top picks include C3.ai, Robinhood, Central Puerto, CF Industries, and Kyndryl.
Positive
Zacks Investment Research
2 weeks ago
JAZZ or ARGX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Charts implemented using Lightweight Charts™